'에이비엘바이오' 과거의 영광 되찾을 수 있을까? 하반기 반등 트리거 총정리

[Filming Date: June 16, 2026] Hello, this is Haejin Lee from Bio Investment School. Today, I have summarized the key variables for the second half of the year for ABL Bio, whose stock price has recently undergone a significant correction. Although ABL Bio is a company with a history of technology transfers with global big pharma firms such as Sanofi, GSK, and Eli Lilly, its stock price has been showing a weak trend due to a combination of the recent slump in the bio sector as a whole and concerns regarding its major pipelines. In this video, we examined what ABL Bio's core platforms, GrabBody-T and GrabBody-B, are, as well as the clinical trial schedules and technology transfer possibilities that investors must check in the second half of the year. In particular, the most important point is ABL111. ABL111, targeting the market for first-line gastric cancer treatments, is set to release follow-up data in the second half of the year. If positive data is maintained, it is a pipeline that holds the potential for a large-scale technology transfer. In addition, we examined the clinical reorganization and potential for follow-up entry of ABL301, as well as the pre-NDA meeting for ABL001, as key variables for the second half of the year. For ABL Bio to regain its past strong momentum, it needs actual data and technology transfer achievements, not just mere expectations. Please check this video to identify the triggers for ABL Bio's rebound in the second half and the key conditions investors need to watch. Thank you for joining us today. ※ This channel is operated by a quasi-investment advisory firm, not a financial investment firm; therefore, individual investment consultations and fund management are not available. All information provided on this site is for reference purposes only for investment decisions, and principal loss may occur; such losses are borne by the investor.